Cellular Mechanisms of Bsarrett's Esophagus Development

Surgical Oncology Clinics of North America

Volumn 18, Issue 3, 2009, Pages 393-410

  Barbera, Mariagnese ^a   Fitzgerald, Rebecca C ^a,b  

^a HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Acid; Bile; GERD; Metaplasia; Stem cells

Indexed keywords

ANTIBODY; DNA; PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; BILE REFLUX; CELL DIFFERENTIATION; CELL FATE; CELL POPULATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; DEFENSE MECHANISM; DISEASE COURSE; DNA DAMAGE; DUODENUM; DYSPLASIA; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; GENE MUTATION; HUMAN; INTESTINE; LONG TERM EXPOSURE; METAPLASIA; MICROENVIRONMENT; MULTIPOTENT STEM CELL; NONHUMAN; REVIEW; TISSUE INJURY; ADENOCARCINOMA; ANEUPLOIDY; ANIMAL; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION; COCARCINOGENESIS; DISEASE MODEL; ESOPHAGUS TUMOR; GENETIC EPIGENESIS; INFLAMMATION; MUTATION; PATHOLOGY; PHYSIOLOGY; PRECANCER; RISK FACTOR; STEM CELL;

ADENOCARCINOMA; ANEUPLOIDY; ANIMALS; BARRETT ESOPHAGUS; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; COCARCINOGENESIS; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; INFLAMMATION; METAPLASIA; MULTIPOTENT STEM CELLS; MUTATION; PRECANCEROUS CONDITIONS; RISK FACTORS; STEM CELLS;

EID: 66149108790     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2009.03.001     Document Type: Review

References (105)

1. Tosh D., and Slack J.M. How cells change their phenotype. Nat Rev Mol Cell Biol 3 (2002) 187-194
2. Vaezi M.F., and Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 111 (1996) 1192-1199
3. Hamilton S.R., and Yardley J.H. Regnerative of cardiac type mucosa and acquisition of Barrett mucosa after esophagogastrostomy. Gastroenterology 72 (1977) 669-675
4. Nakanishi Y., Saka M., Eguchi T., et al. Distribution and significance of the oesophageal and gastric cardiac mucosae: a study of 131 operation specimens. Histopathology 51 (2007) 515-519
5. Li H., Walsh T.N., O'Dowd G., et al. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 115 (1994) 176-181
6. Yu W.Y., Slack J.M., and Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev Biol 284 (2005) 157-170
7. Barham C.P., Jones R.L., Biddlestone L.R., et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 41 (1997) 281-284
8. Shields H.M., Rosenberg S.J., Zwas F.R., et al. Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am J Gastroenterol 96 (2001) 3268-3273
9. Seery J.P. Stem cells of the oesophageal epithelium. J Cell Sci 115 (2002) 1783-1789
10. Clayton E., Doupe D.P., Klein A.M., et al. A single type of progenitor cell maintains normal epidermis. Nature 446 (2007) 185-189
11. Rochat A., Kobayashi K., and Barrandon Y. Location of stem cells of human hair follicles by clonal analysis. Cell 76 (1994) 1063-1073
12. Guillem P.G. How to make a Barrett esophagus: pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci 50 (2005) 415-424
13. Ahnen D.J., Poulsom R., Stamp G.W., et al. The ulceration-associated cell lineage (UACL) reiterates the Brunner's gland differentiation programme but acquires the proliferative organization of the gastric gland. J Pathol 173 (1994) 317-326
14. Coad R.A., Woodman A.C., Warner P.J., et al. On the histogenesis of Barrett's oesophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native oesophageal gland ducts. J Pathol 206 (2005) 388-394
15. Chang C.L., Lao-Sirieix P., Save V., et al. Retinoic acid-induced glandular differentiation of the oesophagus. Gut 56 (2007) 906-917
16. Abdulnour-Nakhoul S., Nakhoul N.L., Wheeler S.A., et al. Characterization of esophageal submucosal glands in pig tissue and cultures. Dig Dis Sci 52 (2007) 3054-3065
17. Leedham S.J., Preston S.L., McDonald S.A., et al. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. Gut 57 8 (2008) 1041-1048
18. Paulson T.G., Xu L., Sanchez C., et al. Neosquamous epithelium does not typically arise from Barrett's epithelium. Clin Cancer Res 12 (2006) 1701-1706
19. Sarosi G., Brown G., Jaiswal K., et al. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus 21 (2008) 43-50
20. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 306 (2004) 1568-1571
21. Miyashita T., Ohta T., Fujimura T., et al. Duodenal juice stimulates oesophageal stem cells to induce Barrett's oesophagus and oesophageal adenocarcinoma in rats. Oncol Rep 15 (2006) 1469-1475
22. McDonald S.A., Greaves L.C., Gutierrez-Gonzalez L., et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology 134 (2008) 500-510
23. Bremner C.G., Lynch V.P., and Ellis Jr. F.H. Barrett's esophagus: congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 68 (1970) 209-216
24. Kahrilas P.J., Dodds W.J., Hogan W.J., et al. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 91 (1986) 897-904
25. Tharalson E.F., Martinez S.D., Garewal H.S., et al. Relationship between rate of change in acid exposure along the esophagus and length of Barrett's epithelium. Am J Gastroenterol 97 (2002) 851-856
26. Peters F.T., Ganesh S., Kuipers E.J., et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 45 (1999) 489-494
27. Peters F.T., Ganesh S., Kuipers E.J., et al. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Scand J Gastroenterol 35 (2000) 1238-1244
28. Hillman L.C., Chiragakis L., Shadbolt B., et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 27 (2008) 321-326
29. Lao-Sirieix P., Roy A., Worrall C., et al. Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 288-293
30. de Jonge P.J., Siersema P.D., van Breda S.G., et al. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Aliment Pharmacol Ther 28 1 (2008) 127-136
31. Tobey N.A., Reddy S.P., Keku T.O., et al. Mechanisms of HCl-induced lowering of intracellular pH in rabbit esophageal epithelial cells. Gastroenterology 105 (1993) 1035-1044
32. Lao-Sirieix P., Corovic A., Jankowski J., et al. Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Dis Esophagus (2007) doi:10.1111/j.1442-2050.2007.00796.x
33. Tobey N.A., Cragoe Jr. E.J., and Orlando R.C. HCl-induced cell edema in rabbit esophageal epithelium: a bumetanide-sensitive process. Gastroenterology 109 (1995) 414-421
34. Orlando R.C., Bryson J.C., and Powell D.W. Mechanisms of H+ injury in rabbit esophageal epithelium. Am J Physiol 246 (1984) G718-G724
35. Namiot Z., Sarosiek J., Marcinkiewicz M., et al. Declined human esophageal mucin secretion in patients with severe reflux esophagitis. Dig Dis Sci 39 (1994) 2523-2529
36. Guillem P., Billeret V., Buisine M.P., et al. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer 88 (2000) 856-861
37. Tobey N.A., Reddy S.P., Khalbuss W.E., et al. Na(+)-dependent and -independent Cl-/HCO3- exchangers in cultured rabbit esophageal epithelial cells. Gastroenterology 104 (1993) 185-195
38. Hollwarth M.E., Smith M., Kvietys P.R., et al. Esophageal blood flow in the cat: normal distribution and effects of acid perfusion. Gastroenterology 90 (1986) 622-627
39. Meyer W., Vollmar F., and Bar W. Barrett-esophagus following total gastrectomy: a contribution to its pathogenesis. Endoscopy 11 (1979) 121-126
40. Gutschow C.A., Vallbohmer D., Stolte M., et al. Adenocarcinoma developing in de novo Barrett's mucosa in the remnant esophagus after esophagectomy: clinical and molecular assessment. Dis Esophagus 21 (2008) E6-E8
41. Seto Y., and Kobori O. Role of reflux oesophagitis and acid in the development of columnar epithelium in the rat oesophagus. Br J Surg 80 (1993) 467-470
42. Kivilaakso E., Fromm D., and Silen W. Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 87 (1980) 280-285
43. Eda A., Osawa H., Satoh K., et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 38 (2003) 14-22
44. Pera M., Pera M., de Bolos C., et al. Duodenal-content reflux into the esophagus leads to expression of Cdx2 and Muc2 in areas of squamous epithelium in rats. J Gastrointest Surg 11 (2007) 869-874
45. Hu Y., Williams V.A., Gellersen O., et al. The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg 11 (2007) 827-834
46. Kazumori H., Ishihara S., Rumi M.A., et al. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55 (2006) 16-25
47. Lechner S., Muller-Ladner U., Schlottmann K., et al. Bile acids mimic oxidative stress induced upregulation of thioredoxin reductase in colon cancer cell lines. Carcinogenesis 23 (2002) 1281-1288
48. Wilson K.T., Fu S., Ramanujam K.S., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58 (1998) 2929-2934
49. Winter J.W., Paterson S., Scobie G., et al. N-nitrosamine generation from ingested nitrate via nitric oxide in subjects with and without gastroesophageal reflux. Gastroenterology 133 (2007) 164-174
50. Clemons N.J., McColl K.E., and Fitzgerald R.C. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133 (2007) 1198-1209
51. Jang T.J., Min S.K., Bae J.D., et al. Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett's metaplasia induced by duodenal contents reflux. Gut 53 (2004) 27-33
52. Jolly A.J., Wild C.P., and Hardie L.J. Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 19 (2004) 319-324
53. Feagins L.A., Zhang H.Y., Zhang X., et al. Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines. Am J Physiol Gastrointest Liver Physiol 294 2 (2008) G411-G417
54. Dvorak K., Chavarria M., Payne C.M., et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bile acids and low pH: relevance to barrett's esophagus. Clin Cancer Res 13 (2007) 5305-5313
55. Tselepis C., Perry I., Dawson C., et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21 (2002) 6071-6081
56. Moons L.M., Kusters J.G., Bultman E., et al. Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol 207 (2005) 269-276
57. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M., et al. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50 (2002) 451-459
58. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 51 (2002) 316-322
59. Johansson M., Denardo D.G., and Coussens L.M. Polarized immune responses differentially regulate cancer development. Immunol Rev 222 (2008) 145-154
60. Moons L.M., Kusters J.G., van Delft J.H., et al. A pro-inflammatory genotype predisposes to Barrett's esophagus. Carcinogenesis 29 5 (2008) 926-931
61. Rabinovitch P.S., Longton G., Blount P.L., et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 96 (2001) 3071-3083
62. Chaves P., Crespo M., Ribeiro C., et al. Chromosomal analysis of Barrett's cells: demonstration of instability and detection of the metaplastic lineage involved. Mod Pathol 20 (2007) 788-796
63. Meltzer S.J., Yin J., Manin B., et al. Microsatellite instability occurs frequently and in both diploid and aneuploid cell populations of Barrett's-associated esophageal adenocarcinomas. Cancer Res 54 (1994) 3379-3382
64. Reid B.J., Haggitt R.C., Rubin C.E., et al. Barrett's esophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 93 (1987) 1-11
65. Fennerty M.B., Sampliner R.E., Way D., et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 97 (1989) 815-820
66. Galipeau P.C., Li X., Blount P.L., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4 (2007) 342-354
67. Gleeson C.M., Sloan J.M., McGuigan J.A., et al. Ubiquitous somatic alterations at microsatellite alleles occur infrequently in Barrett's-associated esophageal adenocarcinoma. Cancer Res 56 (1996) 259-263
68. Olliver J.R., Hardie L.J., Dexter S., et al. DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers 8 (2003) 509-521
69. Olliver J.R., Hardie L.J., Gong Y., et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 14 (2005) 620-625
70. Fitzgerald R.C. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 55 (2006) 1810-1820
71. Daniely Y., Liao G., Dixon D., et al. Critical role of p63 in the development of a normal esophageal and tracheobronchial epithelium. Am J Physiol Cell Physiol 287 (2004) C171-C181
72. Geddert H., Kiel S., Heep H.J., et al. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol 34 (2003) 850-856
73. Roman S., Petre A., Thepot A., et al. Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. Am J Physiol Gastrointest Liver Physiol 293 (2007) G45-G53
74. Yamamoto H., Bai Y.Q., and Yuasa Y. Homeodomain protein CDX2 regulates goblet-specific MUC2 gene expression. Biochem Biophys Res Commun 300 (2003) 813-818
75. Vallbohmer D., DeMeester S.R., Peters J.H., et al. Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis Esophagus 19 (2006) 260-266
76. Moons L.M., Bax D.A., Kuipers E.J., et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 57 (2004) 1063-1068
77. Silberg D.G., Sullivan J., Kang E., et al. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122 (2002) 689-696
78. Reid B.J., Sanchez C.A., Blount P.L., et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105 (1993) 119-129
79. Lao-Sirieix P., Brais R., Lovat L., et al. Cell cycle phase abnormalities do not account for disordered proliferation in Barrett's carcinogenesis. Neoplasia 6 (2004) 751-760
80. Arber N., Lightdale C., Rotterdam H., et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 5 (1996) 457-459
81. Lu F., Gladden A.B., and Diehl J.A. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63 (2003) 7056-7061
82. Umansky M., Yasui W., Hallak A., et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 20 (2001) 7987-7991
83. Lao-Sirieix P., Lovat L., and Fitzgerald R.C. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin Cancer Res 13 (2007) 659-665
84. Tannapfel A. Molecular findings in Barrett's epithelium. Dig Dis 22 (2004) 126-133
85. Barrett M.T., Sanchez C.A., Prevo L.J., et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22 (1999) 106-109
86. Segal F., Kaspary A.P., Prolla J.C., et al. p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Lett 210 (2004) 213-218
87. Merola E., Mattioli E., Minimo C., et al. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J Cell Physiol 207 (2006) 512-519
88. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
89. Huang Y., Peters C.J., Fitzgerald R.C., et al. Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med 13 2 (2009) 398-409
90. Barrett M.T., Sanchez C.A., Galipeau P.C., et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13 (1996) 1867-1873
91. Wong D.J., Paulson T.G., Prevo L.J., et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 61 (2001) 8284-8289
92. Maley C.C., Galipeau P.C., Li X., et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 64 (2004) 3414-3427
93. Maley C.C., Galipeau P.C., Finley J.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38 (2006) 468-473
94. Morales C.P., Lee E.L., and Shay J.W. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 83 (1998) 652-659
95. Lord R.V., Salonga D., Danenberg K.D., et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4 (2000) 135-142
96. Klump B., Hsieh C.J., Holzmann K., et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 115 (1998) 1381-1386
97. Hardie L.J., Darnton S.J., Wallis Y.L., et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 217 (2005) 221-230
98. Vieth M., Schneider-Stock R., Rohrich K., et al. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma. Virchows Arch 445 (2004) 135-141
99. Clement G., Guilleret I., He B., et al. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus. Cancer Sci 99 (2008) 46-53
100. Kawakami K., Brabender J., Lord R.V., et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92 (2000) 1805-1811
101. Clement G., Braunschweig R., Pasquier N., et al. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 25 (2006) 3084-3092
102. Schlesinger Y., Straussman R., Keshet I., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39 (2007) 232-236
103. Liu T., Zhang X., So C.K., et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28 (2007) 488-496
104. Jin Z., Mori Y., Yang J., et al. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 26 (2007) 6332-6340
105. Jin Z., Hamilton J.P., Yang J., et al. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 17 (2008) 111-117